Literature DB >> 17257275

The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program.

.   

Abstract

AIMS: Retinopathy is considered the complication most closely associated with and characteristic of diabetes mellitus. Hyperglycaemia below levels diagnostic of diabetes, so called pre-diabetes, is associated with a low prevalence of 'diabetic' retinopathy. However, few longitudinal studies of non-diabetic populations have performed repeated measures of glycaemia and screened for retinopathy to determine its occurrence in the non-diabetic population and the onset of retinopathy in new-onset diabetic patients. We determined the prevalence of retinopathy characteristically seen in diabetes in persons with impaired glucose tolerance and in patients with new-onset diabetes of known duration in the Diabetes Prevention Program (DPP) cohort.
METHODS: The DPP recruited persons with elevated fasting glucose (5.3-6.9 mmol/l) and impaired glucose tolerance, and no history of diagnosed diabetes, other than gestational diabetes not persisting after pregnancy. Seven-field, stereoscopic fundus photography was completed a mean of 3.1 years after the development of diabetes in 594 of 878 participants who had developed diabetes during the DPP, and in a random sample of 302 participants who remained non-diabetic.
RESULTS: Retinopathy consistent with diabetic retinopathy was detected in 12.6 and 7.9% of the diabetic and non-diabetic participants, respectively (P = 0.03, comparing prevalence in the two groups). Systolic blood pressure and HbA(1c) were higher at baseline in the diabetic participants who had retinopathy compared with the diabetic participants without retinopathy.
CONCLUSIONS: Retinopathy characteristic of diabetes is present in persons with elevated fasting glucose and impaired glucose tolerance and no known history of diabetes. The prevalence of retinopathy is significantly higher in persons who develop diabetes, even within 3 years of diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17257275      PMCID: PMC2267935          DOI: 10.1111/j.1464-5491.2007.02043.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  23 in total

Review 1.  Follow-up report on the diagnosis of diabetes mellitus.

Authors:  Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

2.  Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading.

Authors:  W J Sluiter; D W Erkelens; W D Reitsma; H Doorenbos
Journal:  Diabetes       Date:  1976-04       Impact factor: 9.461

3.  The prevalence and risk factors of retinal microvascular abnormalities in older persons: The Cardiovascular Health Study.

Authors:  Tien Yin Wong; Ronald Klein; A Richey Sharrett; Teri A Manolio; Larry D Hubbard; Emily K Marino; Lewis Kuller; Gregory Burke; Russell P Tracy; Joseph F Polak; John S Gottdiener; David S Siscovick
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

4.  Hypertensive eye ground changes. Prevalence, relation to blood pressure and prognostic importance. The study of men born in 1913.

Authors:  K Svärdsudd; H Wedel; E Aurell; G Tibblin
Journal:  Acta Med Scand       Date:  1978

5.  The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.

Authors:  H M Leibowitz; D E Krueger; L R Maunder; R C Milton; M M Kini; H A Kahn; R J Nickerson; J Pool; T L Colton; J P Ganley; J I Loewenstein; T R Dawber
Journal:  Surv Ophthalmol       Date:  1980 May-Jun       Impact factor: 6.048

6.  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

7.  A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes.

Authors:  Biljana Miljanovic; Robert J Glynn; David M Nathan; Joann E Manson; Debra A Schaumberg
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

8.  The natural history of retinopathy in insulin-dependent juvenile-onset diabetes.

Authors:  P Palmberg; M Smith; S Waltman; T Krupin; P Singer; D Burgess; T Wendtlant; J Achtenberg; P Cryer; J Santiago; N White; C Kilo; W Daughaday
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

9.  Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis.

Authors:  M I Harris; R Klein; T A Welborn; M W Knuiman
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

10.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04
View more
  92 in total

Review 1.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.

Authors:  Q Gong; E W Gregg; J Wang; Y An; P Zhang; W Yang; H Li; H Li; Y Jiang; Y Shuai; B Zhang; J Zhang; R B Gerzoff; G Roglic; Y Hu; G Li; P H Bennett
Journal:  Diabetologia       Date:  2010-11-03       Impact factor: 10.122

4.  Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.

Authors:  Katherine A Pratte; Ann Johnson; Janette Beals; Ann Bullock; Spero M Manson; Luohua Jiang
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

5.  Prevalence and risk factors of diabetic retinopathy in Chongqing pre-diabetes patients.

Authors:  X Chen; Y Zhao; Z Zhou; X Zhang; Q Li; L Bai; M Zhang
Journal:  Eye (Lond)       Date:  2012-03-23       Impact factor: 3.775

Review 6.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

Review 7.  Evidence for current diagnostic criteria of diabetes mellitus.

Authors:  Ritesh Kumar; Lakshmana Perumal Nandhini; Sadishkumar Kamalanathan; Jayaprakash Sahoo; Muthupillai Vivekanadan
Journal:  World J Diabetes       Date:  2016-09-15

8.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

9.  Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds.

Authors:  Yiling J Cheng; Edward W Gregg; Linda S Geiss; Giuseppina Imperatore; Desmond E Williams; Xinzhi Zhang; Ann L Albright; Catherine C Cowie; Ronald Klein; Jinan B Saaddine
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 17.152

Review 10.  Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.